194 related articles for article (PubMed ID: 3374991)
1. Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the ornithine transcarbamylase-deficient sparse-fur mouse.
Batshaw ML; Hyman SL; Coyle JT; Robinson MB; Qureshi IA; Mellits ED; Quaskey S
Pediatr Res; 1988 Apr; 23(4):368-74. PubMed ID: 3374991
[TBL] [Abstract][Full Text] [Related]
2. Effect of sodium benzoate on cerebral and hepatic energy metabolites in spf mice with congenital hyperammonemia.
Ratnakumari L; Qureshi IA; Butterworth RF
Biochem Pharmacol; 1993 Jan; 45(1):137-46. PubMed ID: 8424807
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment of girls with ornithine transcarbamylase deficiency.
Maestri NE; Brusilow SW; Clissold DB; Bassett SS
N Engl J Med; 1996 Sep; 335(12):855-9. PubMed ID: 8778603
[TBL] [Abstract][Full Text] [Related]
4. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders.
Enns GM; Berry SA; Berry GT; Rhead WJ; Brusilow SW; Hamosh A
N Engl J Med; 2007 May; 356(22):2282-92. PubMed ID: 17538087
[TBL] [Abstract][Full Text] [Related]
5. Effect of L-carnitine on cerebral and hepatic energy metabolites in congenitally hyperammonemic sparse-fur mice and its role during benzoate therapy.
Ratnakumari L; Qureshi IA; Butterworth RF
Metabolism; 1993 Aug; 42(8):1039-46. PubMed ID: 8102193
[TBL] [Abstract][Full Text] [Related]
6. Effect of long-term administration of sodium benzoate to a patient with partial ornithine carbamoyl transferase deficiency.
Takeda E; Kuroda Y; Toshima K; Watanabe T; Naito E; Miyao M
Clin Pediatr (Phila); 1983 Mar; 22(3):206-8. PubMed ID: 6825366
[TBL] [Abstract][Full Text] [Related]
7. [Profile of hepatic and muscular acylcarnitines in chronically hyperammonemic mice after an acute treatment with sodium benzoate: dose-response study].
Michalak A; Qureshi IA
Ann Biol Clin (Paris); 1993; 51(10-11):879-85. PubMed ID: 8210064
[TBL] [Abstract][Full Text] [Related]
8. [Carnitine levels in muscle in mice with hyperammonemia: effect of treatment with sodium benzoate].
Michalak A; Qureshi IA
Can J Physiol Pharmacol; 1993 Jul; 71(7):439-46. PubMed ID: 8242478
[TBL] [Abstract][Full Text] [Related]
9. Activity of the glycine cleavage system in hyperammonemia treated with benzoate.
Kodama H; Fujiwara K; Motokawa Y; Tajiri H; Nose O; Kamoshita S
Tohoku J Exp Med; 1983 Jul; 140(3):337-8. PubMed ID: 6623463
[TBL] [Abstract][Full Text] [Related]
10. Prospective management of a child with neonatal citrullinemia.
Melnyk AR; Matalon R; Henry BW; Zeller WP; Lange C
J Pediatr; 1993 Jan; 122(1):96-8. PubMed ID: 8419623
[TBL] [Abstract][Full Text] [Related]
11. Development and inducibility of the hepatic and renal hippurate-synthesizing system in sparse-fur (spf) mutant mice with ornithine transcarbamylase deficiency.
Qureshi IA; Lebel S; Letarte J
Biochem Int; 1989 Sep; 19(3):657-66. PubMed ID: 2818615
[TBL] [Abstract][Full Text] [Related]
12. Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis.
Brusilow SW; Danney M; Waber LJ; Batshaw M; Burton B; Levitsky L; Roth K; McKeethren C; Ward J
N Engl J Med; 1984 Jun; 310(25):1630-4. PubMed ID: 6427608
[TBL] [Abstract][Full Text] [Related]
13. Chronic benzoate therapy in a boy with partial ornithine transcarbamylase deficiency.
Letarte J; Qureshi IA; Ouellet R; Godard M
J Pediatr; 1985 May; 106(5):794-7. PubMed ID: 3998920
[No Abstract] [Full Text] [Related]
14. Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients.
Scaglia F; Carter S; O'Brien WE; Lee B
Mol Genet Metab; 2004 Apr; 81 Suppl 1():S79-85. PubMed ID: 15050979
[TBL] [Abstract][Full Text] [Related]
15. Amino acid acylation: a mechanism of nitrogen excretion in inborn errors of urea synthesis.
Brusilow S; Tinker J; Batshaw ML
Science; 1980 Feb; 207(4431):659-61. PubMed ID: 6243418
[TBL] [Abstract][Full Text] [Related]
16. [Brain monoamines and behavior in hyperammonemic sparse-fur mice].
Minakami K
Nihon Yakurigaku Zasshi; 1994 May; 103(5):219-29. PubMed ID: 8188118
[TBL] [Abstract][Full Text] [Related]
17. Increased densities of binding sites for the peripheral-type benzodiazepine receptor ligand [3H]PK 11195 in congenital ornithine transcarbamylase-deficient sparse fur mouse.
Rao VL; Qureshi IA; Butterworth RF
Pediatr Res; 1993 Dec; 34(6):777-80. PubMed ID: 8108192
[TBL] [Abstract][Full Text] [Related]
18. Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance.
Simell O; Sipilä I; Rajantie J; Valle DL; Brusilow SW
Pediatr Res; 1986 Nov; 20(11):1117-21. PubMed ID: 3099249
[TBL] [Abstract][Full Text] [Related]
19. Hyperammonemic encephalopathy after chemotherapy. Survival after treatment with sodium benzoate and sodium phenylacetate.
del Rosario M; Werlin SL; Lauer SJ
J Clin Gastroenterol; 1997 Dec; 25(4):682-4. PubMed ID: 9451687
[TBL] [Abstract][Full Text] [Related]
20. The sparse fur mouse as a model for gene therapy in ornithine carbamoyltransferase deficiency.
Batshaw ML; Yudkoff M; McLaughlin BA; Gorry E; Anegawa NJ; Smith IA; Hyman SL; Robinson MB
Gene Ther; 1995 Dec; 2(10):743-9. PubMed ID: 8750014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
